AbbVie

March 27, 2018March 27, 2018

An IBD Biologic Does Not Increase Woman’s Risk of Birth Problem, Study Finds

News

Women who take biologics for autoimmune disorders either three months before or during their pregnancy are not at higher risk of a preterm birth or having a smaller than normal ... Read more

December 4, 2017December 4, 2017

18 Organizations Form IBD UK to Improve Crohn’s and Colitis Care Through Collaboration

News

Inflammatory bowel disease has been increasing since the 1960s, burdening not only those who live with IBD but the global healthcare system as well. That has led 18 organizations in ... Read more

November 16, 2017November 16, 2017

EU Approves Humira Biosimilar Cyltezo for Treatment of Chronic Inflammatory Diseases

News

The European Commission recently approved Cyltezo, a biosimilar to Humira (adalimumab), for the treatment of chronic inflammatory diseases in adults and children including inflammatory bowel diseases (IBDs) such as Crohn’s disease ... Read more

August 30, 2017August 30, 2017

FDA Approves Humira Biosimilar Cyltezo for Ulcerative Colitis, Crohn’s Disease, Other Illnesses

News

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim‘s Cyltezo— a biosimilar of Abbvie’s Humira (adalimumab) — to treat Crohn’s disease, ulcerative colitis and a host of other diseases ranging from ... Read more

June 29, 2017

In Celebration of Canada 150, Crohn’s and Colitis Canada and AbbVie Add IBD Scholarships

News

To celebrate Canada 150, Crohn’s and Colitis Canada and AbbVie have announced there will be five additional IBD Scholarships of up to $5,000 to be awarded to students who live ... Read more

May 10, 2017

AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3

News

A Phase 2 trial (NCT02365649) of AbbVie’s investigational compound upadacitinib (ABT-494) showed the treatment had a positive effect in patients with Crohn’s disease, supporting the drug’s advance to Phase 3 ... Read more

December 5, 2016

FDA Grants Orphan Drug Status to AbbVie’s Therapy for Pediatric Crohn’s Disease

News

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AbbVie’s investigational drug risankizumab for the treatment of pediatric patients with Crohn’s disease. Risankizumab (ABBV-066) selectively blocks ... Read more

July 28, 2016

To Raise Awareness of IBD, Soccer Star Brandi Chastain and AbbVie Create ‘Game Plan’

News

Brandi Chastain, a former member of the United States women’s national soccer team and a retired world class professional soccer player recently elected to the U.S. Soccer Hall of Fame, ... Read more

June 7, 2016June 7, 2016

Some Crohn’s Disease Patients Reach Remission with Risankizumab

Crohn's Disease, IBD News, News

Phase 2 clinical trial results showed that patients with moderate to severe active Crohn’s disease can achieve disease remission when treated with risankizumab, a Boehringer Ingelheim investigational biologic product. The study, “IL-23 ... Read more

May 26, 2016May 26, 2016

AbbVie Showcases IBD Therapies at Digestive Disease Week Annual Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

North Chicago, Illinois based multinational biopharmaceutical company AbbVie presented 13 abstracts at the Digestive Disease Week (DDW) Annual Meeting held May 21-24, 2016, at San Diego, California. Abstracts presented addressed ... Read more